PNM3 A COST EFFECTIVENESS ANALYSIS OF ZOLMITRIPTAN NASAL SPRAY  by Annemans, L et al.
762 Abstracts
NEUROLOGICAL DISORDERS/MIGRAINE—Cost
Studies
PNM2
COST-EFFECTIVENESS OF ELETRIPTAN 40MG
COMPARED WITH STANDARD DOSES OF
AVAILABLE TRIPTANS FOR ACUTE MIGRAINE
ATTACKS IN SPAIN
Gracia-Naya M1, Rejas J2, León T3
1Department of Neurology, Hospital Miguel Servet, Zaragoza,
Spain; 2Health Outcomes Research, Medical Unit, Pﬁzer SA,
Alcobendas, Madrid, Spain; 3Medical Unit, Pﬁzer Spain SA,
Alcobendas, Madrid, Spain
OBJECTIVE: To perform an economic evaluation (EE)
comparing eletriptan 40mg with available standard doses
of existing triptans in Spain using different outcome mea-
surements of anti-migraine effectiveness. METHODS:
A cost-effectiveness analysis was performed comparing
eletriptan (E) versus existing triptans available in Spain in
year 2002; sumatriptan (S), almotriptan (A), naratriptan
(N), rizatriptan (R) y zolmitriptan (Z). Effectiveness was
obtained from a meta-analysis of efﬁcacy with published
randomized clinical trials (RCT). Effectiveness measure-
ments were analgesic response within 2 hours (pain
reduction and pain free), usage of rescue medication, and
24 hours response (sustained pain free and recurrence
rate). Number needed to treat (NNT), with its 95% con-
ﬁdence interval was calculated. EE was performed from
the National Health System perspective and drugs cost
are computed only using public selling prices. RESULTS:
A total of 33 RCTs were used to ascertain triptans effec-
tiveness (9.473 patients treated with triptans and 3.432
with placebo). The proportion of patients with headache
response within 2 hours was higher with eletriptan than
with the rest of triptans; 38% versus, respectively, 28%,
25%, 23%, 37%, & 25% for S, Z, N, R, and A. E
showed a lower NTT per successfully treated attacks than
comparators; 2,6 vs, respectively, 3.6, 4.0, 4.3, 2.7, 4.0,
and 2.6. The cost per successfully treated patient was
lower for E; €26.54 versus €30.61, €45.95, €29.69,
€32.41, and €36.06. CONCLUSIONS: The cost per suc-
cessfully treated migraine attack was lower for patients
treated with Eletriptan compared to other existing trip-
tans in Spain.
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OBJECTIVES: To assess the cost-effectiveness of nasal
spray zolmitriptan 5mg (ZOL), compared to subcuta-
neous sumatriptan 6mg (SUM) in the management of
moderate to severe migraine patients in Belgium.
METHODS: A medical decision analytic model was
developed in MS-Excel, reﬂecting patient outcomes and
related management. The net response rate (headache
response after 2 hours) above placebo is a primary
outcome in migraine trials and was obtained from ran-
domised clinical trials. This response rate above placebo
was 52% for SUM, and 39.7% for ZOL. However, recur-
rence rates after initial response and within the same
attack were 39% and only 25.6% respectively. Cost of
non-response and cost of managing recurrence were
obtained from published local literature from a health
care payer perspective. Full response was deﬁned as
patients responding without recurrence. The time horizon
was limited to one attack episode. RESULTS: ZOL total
treatment cost was €28.02 with 43.7% full response,
while SUM costed €40.95 in total with 42.19% full
response (i.e. ZOL slightly dominant). Rank order sta-
bility analyses (ROSA) showed that results were very
robust towards variations in cost of management (max.
deviation in savings of 4%). The analysis was sensitive to
treatment performance and recurrence rates, both having
a weak effect on savings (max deviation in savings of
13%), but with the potential to inverse the dominant
position of ZOL. CONCLUSIONS: ZOL as standard
treatment in moderate to severe migraine is cost saving
from the Belgian health care payer’s perspective compared
to SUM, with comparable effectiveness.
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OBJECTIVE: In Canada, the clinical use of triptans is
restricted by many health plans, despite their proven
superior efﬁcacy in the treatment of moderate to severe
migraine. This analysis estimates the clinical conse-
quences, costs and cost-effectiveness of Rizatriptan com-
pared to other triptans and UC in Ontario, Canada.
METHODS: A decision analytic model was created to
estimate migraine treatment costs and clinical outcomes
observed over a 24-hour period from therapy initiation,
in patients with a diagnosis of moderate to severe
migraine as deﬁned by International Headache Society
(IHS) criteria. Efﬁcacy measures consisted of pain-free
patients at 2 and 4 hours and those sustained pain-free
for the following 2 to 24 hours. Rizatriptan was com-
pared to other triptans based on data from a meta-
analysis, and compared to UC based on other published
data. Costs of therapies were used to determine incre-
mental costs per attack aborted as well as cost per QALY.
Both a Ministry of Health perspective (direct costs) and
